|
1
|
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
|
Antimicrob Agents Chemother
|
2007
|
1.91
|
|
2
|
Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.
|
Antimicrob Agents Chemother
|
2007
|
1.41
|
|
3
|
Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
|
Clin Pharmacokinet
|
2007
|
1.35
|
|
4
|
An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
|
J Clin Pharmacol
|
2009
|
0.78
|
|
5
|
Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
|
Clin Ther
|
2008
|
0.77
|